Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914.
Huber, E.M., Heinemeyer, W., Groll, M.(2015) Structure 23: 407-417
- PubMed: 25599643 
- DOI: 10.1016/j.str.2014.11.019
- Primary Citation of Related Structures:  
- PubMed Abstract: 
Inhibition of the 20S proteasome by bortezomib (Velcade) constitutes a successfully applied therapy for blood cancer. However, emerging resistance restricts its medicinal use. For example, mutations in the proteolytically active β5-subunit of the pro ...